CN Mobile Logo


Pancreatic Cancer

Pancreatic Cancer

The ESPAC-4 trial found that adding capecitabine to gemcitabine in patients with resected pancreatic cancer resulted in an improved estimated 5-year survival rate.

Use of hypofractionated chemoradiation prior to pancreatoduodenectomy resulted in similar resection rates and outcomes vs standard fractionation.

Annual screening of people at high risk for pancreatic ductal adenocarcinoma (PDAC) because of CDKN2A mutations was relatively successful and allowed for the detection of disease in time to perform surgery.

Researchers have identified two species of bacteria linked with periodontal disease in healthy individuals that are associated with a risk of developing pancreatic cancer.

Higher preoperative levels of serum albumin were significantly associated with greater overall survival among patients undergoing resection of pancreatic adenocarcinoma.

An integrated genomic analysis has found that pancreatic cancer can be divided into four specific subtypes based on molecular characteristics. This division could help guide treatment decisions and future research avenues into this difficult malignancy.

Pancreatic cancer patients who received adjuvant therapy at a high-volume center had superior overall survival vs patients who were treated in a community setting.


Subscribe to Pancreatic Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.